Application of edaravone in the treatment of acute cerebral infarction
依达拉奉治疗急性脑梗死的应用

摘要

目的 观察研究依达拉奉治疗急性脑梗死的临床应用效果。方法 依据研究目的，选择我院自2020年12月—2022年1月期间收治的急性脑梗死患者92例作为此次观察研究对象。按照随机数字表法，将所有患者随机分为两组，即治疗组与对照组，每组患者各46例。对照组仅实施常规治疗方式，治疗组则采用依达拉奉治疗，并对比两组治疗前后神经功能损伤与生活能力改善情况及治疗后不良反应发生率和治疗总体有效率。结果 治疗前，治疗组与对照组NIHSS评分与ADL评分差异较小，无统计学意义（P＞0.05）；治疗后，两组神经功能损伤程度及生活能力情况均有明显改善，其中，治疗组NIHSS评分及ADL评分均优于对照组，有统计学意义（P＜0.05）；治疗后，对照组不良反应发生率同比治疗组更高，有统计学意义（P＜0.05）；同时，治疗组治疗总有效率远高于对照组，有统计学意义（P＜0.05）。结论 针对急性脑梗死患者实施依达拉奉治疗的临床效果比较理想，有效缓解患者临床症状，降低治疗不良反应率，增强神经损伤恢复能力，抑制细胞毒性，继而提升脑梗死预后能力，提升生活能力，使治疗效果提高。依达拉奉治疗安全性较高，具有较高的临床广泛应用价值。

Abstract

Objective To observe the clinical effect of edaravone in the treatment of acute cerebral infarction.
Methods According to the research purpose, 92 patients with acute cerebral infarction admitted to our hospital from December 2020 to January 2022 were selected as the subjects of this observation. According to the random number table method, all patients were randomly divided into two groups, namely the treatment group and the control group, with 46 patients in each group. The control group only received conventional treatment, while the treatment group was treated with edaravone. The neurological damage and improvement of living ability, the incidence of adverse reactions after treatment and the overall effective rate of treatment were compared between the two groups before and after treatment.
Results Before treatment, the difference in NIHSS score and ADL score between the treatment group and the control group was small, and there was no statistical significance (P>0.05). The NIHSS score and ADL score were better than those in the control group, with statistical significance (P<0.05); after treatment, the incidence of adverse reactions in the control group was higher than that in the treatment group, with statistical significance (P<0.05). The total effective rate of treatment was much higher than that of the control group, with statistical significance (P<0.05).
Conclusion   The clinical effect of edaravone treatment for patients with acute cerebral infarction is ideal, it can effectively relieve the clinical symptoms of patients, reduce the rate of adverse reactions, enhance the ability to recover from nerve damage, inhibit cytotoxicity, and then improve the prognosis of cerebral infarction and improve the ability to live, to improve the treatment effect. Edaravone has high safety and high clinical value.